Compare OPAL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | MAIA |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 79.0M |
| IPO Year | 2021 | 2022 |
| Metric | OPAL | MAIA |
|---|---|---|
| Price | $2.12 | $1.42 |
| Analyst Decision | Sell | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.72 | N/A |
| AVG Volume (30 Days) | 165.0K | ★ 323.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $348,975,000.00 | N/A |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $0.87 |
| 52 Week High | $2.87 | $3.19 |
| Indicator | OPAL | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 52.18 |
| Support Level | $2.00 | $1.36 |
| Resistance Level | $2.44 | $1.46 |
| Average True Range (ATR) | 0.18 | 0.05 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 1.41 | 37.93 |
OPAL Fuels Inc is a fully integrated leader in the capture and conversion of biogas into low-carbon-intensity renewable natural gas and Renewable Power. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-decarbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas. The Company has three operating segments: RNG Fuel, Fuel Station Services, and Renewable Power.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.